Title: Sofosbuvir: an anti-viral drug with potential efficacy against Zika infection
|
|
- Anne Barber
- 6 years ago
- Views:
Transcription
1 Title: Sofosbuvir: an anti-viral drug with potential efficacy against Zika infection Author: id="aut0005" author-id="s x- 1f9e9470cef66741e2bd891010ce1a6f"> Sandra E. Reznik id="aut0010" author-id="s x- 8a42350b8a62aef19db93bc3bffc7af9"> Jr. Charles R. Ashby PII: S (16)31654-X DOI: Reference: IJID 2808 To appear in: International Journal of Infectious Diseases Received date: Revised date: Accepted date: Please cite this article as: Reznik SE, Ashby JrCR, Sofosbuvir: an anti-viral drug with potential efficacy against Zika infection, International Journal of Infectious Diseases (2016), This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
2 Highlights There is an 80% overlap in the amino acids of Zika and hepatitis C virus RNA polymerase that bind sofosbuvir We propose the use of the anti-hcv drug, sofosbuvir, to treat symptomatic Zika infections Sofosbuvir (12 week regimen) has a favorable safety profile in HCV patients Sofosbuvir has not been reported to produce teratogenic or mutagenic effects in humans Sofosbuvir may reduce neurological problems in infants born to symptomatic mothers 1 Page 1 of 9
3 Sofosbuvir: an anti-viral drug with potential efficacy against Zika infection Sandra E. Reznik, M.D., Ph.D. 1, 2 and Charles R. Ashby, Jr., Ph.D. 1 1 Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John s University, Queens, NY 2 Departments of Pathology and Obstetrics and Gynecology and Women s Health, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY 2 Page 2 of 9
4 Currently, there are no effective licensed vaccines or drugs available for the treatment of Zika virus infections and financial support for their development is running short. We suggest that sofosbuvir be considered for Zika infection. Sofosbuvir is used with other drugs for the treatment of hepatitis C virus (HCV) genotypes 1-6 infections. Zika is a member of the flaviviridae family of viruses, which includes yellow fever virus, West Nile virus, dengue virus, St. Louis encephalitis virus and HCV. 1 The most common manifestations include macular or papular rash, fever, arthralgia, retro-orbital pain, conjunctivitis, myalgia and headache and these resolve within two weeks. 2 However, Zika viral outbreaks in the Americas and Pacific have been reported to be temporally linked to Guillain-Barré syndrome. 2,3 Also, acute myelitis and meningoencephalitis have occurred in patients infected with Zika virus. 2,3 There is substantial evidence indicating the Zika virus can be transmitted from the mother to the fetus, resulting in adverse fetal effects, including stillbirths, miscarriages, microcephaly and ocular abnormalities. 3 On February 1, 2016, the WHO declared Zika virus to be a public health emergency of international concern. Zika virus, as with other flaviruses, is an enveloped, single-stranded positive-sensed RNA virus. 4 It has been hypothesized that Zika virus uses the enzyme RNA-dependent RNA polymerase (RdRp or the nonstructural protein, NS5), along with cofactors, to replicate, maintain and express its RNA genome. 4 The three dimensional structure of flavivirus RdRp resembles that of a cupped right hand and contains a finger, thumb and palm domain and is conserved. 4 Currently, the structure of the Zika viral RdRp remains to be 3 Page 3 of 9
5 elucidated. However, the predicted three dimensional structure and amino acids for Zika virus RdRp indicates that hepatitis C virus (HCV) RdRp (NS5B protein), particularly at the active site, shares many residues in common with Zika RdRp. 4 Furthermore, the pharmacologically active metabolite of sofosbuvir, 2 -fluoro-2-c-methyl-utp, which inhibits HCV RdRp, docks into the active site of NS5. 4 Thus, it is possible that certain nucleoside and nucleotide compounds that inhibit HCV RdRp may have inhibitory potency against Zika virus. Zika virus RdRp is an excellent pharmacological target as 1) its inhibition will prevent RNA synthesis and decrease viral replication; 2) there is no similar protein target in human cells. Sofosbuvir is a uridine nucleotide analog that is biotransformed in hepatocytes to a triphosphate metabolite that inhibits HCV RdRp-catalyzed RNA synthesis, thereby inhibiting viral replication and transcription. 5 Interestingly, the triphosphate metabolite of the nucleoside analog 7-deaza-2 -C-methyladenosine, which inhibits HCV RdRp in vitro, has been shown to: 1) inhibit the in vitro replication of Zika virus, as well as other flaviviruses; 2) significantly decrease Zika viremia and delay morbidity and mortality in Zika-infected mice. 6 Congruent with the above findings, certain 2 -C-methylated nucleosides have been shown to inhibit Zika virus replication in cell cultures. 7 Two recent studies indicate that sofosbuvir significantly fits or docks into the Zika virus RdRp. 8,9 Furthermore, there is an 80% overlap in amino acid sequence for the Zika and HCV RdRp s that bind sofosbuvir. 9 In vitro data indicate that sofosbuvir inhibits 1) Brazilian Zika virus RdRp in a concentration-dependent manner; 2) Brazilian Zika viral 4 Page 4 of 9
6 replication in BHK-21 (baby hamster kidney) and SH-Sy5y (human neuroblastoma) cells. 9 Finally, a recent study has shown that BCX4430, an adenosine nucleoside analog, significantly 1) reduces the cytopathic effect of three different Zika strains in vitro; 2) decreases mortality in AG129 mice (which lack Type I and Type II interferon receptors, 300 mg/kg/day); 3) protects AG129 mice from mortality when given one day after Zika virus challenge. 10 We propose that prior to clinical trials, sofosbuvir s efficacy, along with the positive control, 7-deaza-2 -C-methyladenosine, be tested: 1) in vitro against the most common circulating strains of Zika virus to determine if sofosbuvir inhibits viral replication; 2) in vivo in AG129 mice infected with Zika, where its effect on viremia and morbidity and mortality would be assessed. If these results are positive, sofosbuvir s efficacy in humans could be tested in randomized controlled trials by recruiting non-pregnant patients (female patients would be tested for pregnancy) aged 18 or older with Zika virus infection proven by RT PCR of blood or urine and clinical manifestation of the disease present for a minimum of two days. Patients would be screened for other arboviruses (notably Dengue and Chikungunya) as these viruses can elicit similar signs and symptoms as Zika virus. Viral load would be assessed in blood, urine, semen and vaginal secretions throughout treatment. Based on our hypothesis that sofosbuvir will produce significant attenuation of symptoms as compared to placebo control in at least 50% of patients (with a 95% confidence interval of 40 to 60%), treatment and placebo control groups of 100 participants each would be sufficient to detect a statistically significant effect of the drug. Sofosbuvir could be administered orally, 400 mg per day for one week. 5 Page 5 of 9
7 If this initial trial were successful, symptomatic pregnant women with proven Zika virus infection could then be recruited for a similar trial of 400 mg of sofosbuvir per day for one week. Sofosbuvir has a pharmacokinetic profile that would be suitable for treating the potential variety of patients with Zika virus. For example, at least 80% of a dose of sofosbuvir is absorbed systemically and can be given without regard to food. 11 The primary metabolite of sofosbuvir, GS , is pharmacologically inactive, non-toxic and primarily excreted unchanged into the urine. 11 The kinetics of sofosbuvir are not significantly altered by age (19 to 75 years of age), ethnicity, gender, body mass index or cirrhosis. 11 In addition, sofosbuvir and GS have linear pharmacokinetics with minimal accumulation after multiple dosing. 11 Sofosbuvir has a large volume of distribution (127 liters), thereby increasing the likelihood that sufficient concentrations will be present in potential reservoir areas. Sofosbuvir can be used in patients with severe liver impairment and mild-moderate impairment of renal function. 11 Safety would not appear to be of major concern as the majority of adverse effects reported for 400 mg of sofosbuvir were of grade 1 severity in HCV patients and only 1% of patients discontinued treatment. 12 Nonetheless, if sofosbuvir produced intolerable or severe adverse effects or increased mortality, then treatment would be promptly discontinued. Patients should be screened for HCV as using sofosbuvir alone for the treatment of HCV would not be considered optimal therapy. Currently, no well 6 Page 6 of 9
8 controlled or adequate studies have been done using sofosbuvir in pregnant women. However, to date, no teratogenic effects in humans have been reported. Animal data indicate that at area under the curve exposures far exceeding those seen with normal clinical doses, sofosbuvir does not produce carcinogenesis, mutagenic effects, or an impairment of fertility. 13 In summary, we propose that sofosbuvir is a safe pharmacotherapeutic approach for a currently escalating global health threat for which there is currently no effective treatment. If sofosbuvir significantly reduces or eliminates Zika viral load, this approach could 1) in symptomatic cases, eliminate the presence of the virus in plasma, saliva, semen and other body fluids and the risk of transmission between individuals; 2) potentially reduce the severe neurological complications currently seen in infants born to symptomatic mothers. The use of sofosbuvir, in combination with other health-related measures (e.g. control of Zika viral vectors), has the potential to attenuate the health problems and consequences associated with Zika viral infection. Conflict of Interest Statement: The authors declare that there are no conflicts of interest. Funding: None 7 Page 7 of 9
9 1. Weaver SC, Costa F, Garcia-Blanco MA, Koop AI, Ribeiro GS, Saade G, Shi PY et al. Zika virus: History, emergence, biology, and prospects for control. Antiviral Res. 2016;130: Musso D, Gubler DJ. Zika Virus. Clin Microbiol Rev. 2016;29(3): Petersen LR, Jamieson DJ, Powers AM, Honein MA. Zika virus. N Engl J Med. 2016;374(16): Cox BD, Stanton RA, Schinazi RF. Predicting Zika virus structural biology: Challenges and opportunities for intervention. Antivir Chem Chemother. 2016;24: Sofia MJ. Nucleotide prodrugs for the treatment of HCV infection. Adv Pharmacol. 2013;67: Zmurko J, Marques RE, Schols D, Verbeken E, Kaptein SJ, Neyts J. The viral inhibitor 7-deaza-2 -C-methyladenosine is a potent inhibitor of in vitro Zika virus replication and delays disease progression in a robust mouse infection model. PLoS Negl Trop Dis. 2016;10(5):e Page 8 of 9
10 7. Eyer L, Nencka R, Huvarova I, Palus M, Joao Alves M, Gould EA, De Clercq E et al. Nucleoside inhibitors of Zika virus. J Infect Dis. 2016;214: Elfiky AA. Zika viral polymerase inhibition using anti-hcv drugs both in the market and under clinical trials. J Med Virol. 2016;88: Sacramento CQ, de Melo GR, Rocha N, Hoelz LVB, Mesquita M, de Freitas CS, Fintelman-Rodrigues et al. The clinically approved antiviral drug Sofosbuvir impairs Brazilian Zika virus replication. BioRxiv. 2016; doi:http//dx.doi.org/ / Julander JG, Siddharthan V, Evans J, Taylor R, Tolbert K, Apuli C, Stewart J et al. Efficacy of the broad-spectrum antiviral compound BCX4430 against Zika virus in cell culture and in a mouse model. Antiviral Res. 2016; doi: /j.antiviral Kirby BJ, Symonds WT, Kearney BP, Mathias AA. Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir. Clin Pharmacokinet. 2015;54: Keating GM, Vaidya A. Sofosobuvir: First global approval. Drugs. 2014;74: Product information. Sovaldi (sofosbuvir). Foster City, CA: Gilead Sciences, Inc., August Page 9 of 9
Public Health Image Library. CDC/ Cynthia Goldsmith. Image #
Zika Virus Fredrick M. Abrahamian, D.O., FACEP, FIDSA Clinical Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical Center Sylmar,
More informationZika virus: a new global threat for Dr Gina McAllister Clinical Scientist, Virology
Zika virus: a new global threat for 2016 Dr Gina McAllister Clinical Scientist, Virology Moritz U. G. Kraemer and others The global distribution of the arbovirus vectors Aedes aegypti and Ae. albopictus
More informationWhen infections go viral Zika Virus
When infections go viral Zika Virus John Fangman, MD Associate Professor of Medicine (Infectious Diseases) Senior Medical Director of Ambulatory, Medical College Physicians Medical College of Wisconsin
More informationZIKA VIRUS. John J. Russell MD May 27, 2016
John J. Russell MD May 27, 2016 HISTORY Discovered 1947 Zika Forest of Uganda in rhesus monkeys, thus the name Found in humans in Africa in 1952 Not considered a public health threat until outbreak in
More informationZika Virus: The Olympics and Beyond
Zika Virus: The Olympics and Beyond Alice Pong, MD Pediatric Infectious Diseases Rady Children s Hospital-San Diego University of California, San Diego Disclosures I have no disclosures to report 1 Objectives
More informationZIKA Jordan H. Perlow MD Banner University Medical Center Division of Maternal Fetal Medicine Phoenix Perinatal Asoociates
ZIKA Jordan H. Perlow MD Banner University Medical Center Division of Maternal Fetal Medicine Phoenix Perinatal Asoociates Disclosures I have no relevant financial relationships to disclose or conflicts
More informationFact Sheet for Health Care Providers: Interpreting Results from the Aptima Zika Virus assay. September 7, 2016
Dear Health Care Provider: Fact Sheet for Health Care Providers: Interpreting Results from the Aptima Zika Virus assay September 7, 2016 The U.S. Food and Drug Administration (FDA) has issued an Emergency
More informationZika Virus. Centers for Disease Control and Prevention
Centers for Disease Control and Prevention Zika Virus Ingrid Rabe Medical Epidemiologist Arboviral Diseases Branch Centers for Disease Control and Prevention February 1, 2016 Zika Virus Single stranded
More informationWrapping Our Heads Around the Outbreak
Wrapping Our Heads Around the Outbreak An Update on the Zika Virus P. Zach White, PharmD PGY1 Pharmacy Resident Mayo Eugenio Litta Children s Hospital Pharmacy Grand Rounds June 7, 2016 2015 MFMER slide-1
More informationEpidemiology and entomology of the Zika virus outbreak
Epidemiology and entomology of the Zika virus outbreak M A T T H E W B A Y L I S I N S T I T U T E O F I N F E C T I O N A N D G L O B A L H E A L T H U N I V E R S I T Y O F L I V E R P O O L Zika in
More informationWhat s Lurking out there??????
What s Lurking out there?????? Dave Warshauer, PhD, D(ABMM) Deputy Director, Communicable Diseases Wisconsin State Laboratory of Hygiene david.warshauer@slh.wisc.edu WISCONSIN STATE LABORATORY OF HYGIENE
More informationZika: Deet, There It Is. Anna Powell, MD Reproductive Infectious Disease Fellow THEGOS
Zika: Deet, There It Is Anna Powell, MD Reproductive Infectious Disease Fellow THEGOS Disclosure I have no financial disclosures or conflicts of interest Lessons from Rubella At peak of rubella epidemic
More informationGuidance for Investigation and Management of Zika Virus Infection
Guidance for Investigation and Management of Zika Virus Infection Update: February 11, 2016 Public Health Agency of Canada has issued recommendations from the Committee to Advise on Tropical Medicine and
More informationZika virus: Interim guidance information for LMCs (midwives), GPs and other health professionals dealing with Zika virus in pregnancy 5 February 2016
Zika virus: Interim guidance information for LMCs (midwives), GPs and other health professionals dealing with Zika virus in pregnancy 5 February 2016 This interim guidance is the result of consultation
More informationModule Three About Zika Virus: What is Known and Not Known
Module Three About Zika Virus: What is Known and Not Known HOUSEKEEPING For educational and quality improvement purposes, this TeleECHO Clinic will be recorded By participating in this clinic, you are
More informationOutbreaks of Zika Virus: What Do We Know? Presented by Dr Jonathan Darbro Mosquito Control Lab, QIMR Berhgofer 15 September 2016
Outbreaks of Zika Virus: What Do We Know? Presented by Dr Jonathan Darbro Mosquito Control Lab, QIMR Berhgofer 15 September 2016 Overview History Distribution Modes of Transmission Symptoms Some Causal
More informationZika and Emerging Infectious Diseases. Clifford T. Mauriello, MD, FAAP Assistant Clinical Professor May 31, 2016
Zika and Emerging Infectious Diseases Clifford T. Mauriello, MD, FAAP Assistant Clinical Professor May 31, 2016 Famous Last Words The time has come to close the book on infectious diseases. We have basically
More informationZika Virus Update for Emergency Care Providers
Zika Virus Update for Emergency Care Providers What is this Zika Virus? Jeff Doerr Epidemiologist Southeastern Idaho Public Health Zika Virus Single stranded RNA virus Genus Flavivirus, Family Flaviviridae
More informationZika Virus. ZIKA VIRUS & PREGNANCY Stephen Champlin, M.D. FLAVIVIRIDAE VIRUS SPECTRUM. Virus family Flaviviridae
ZIKA VIRUS & PREGNANCY Stephen Champlin, M.D. Zika Virus Virus family Flaviviridae Positive sense, single-stranded RNA virus FLAVIVIRIDAE VIRUS SPECTRUM Arbovirus - spread by arthropods to mammals Flaviviridae
More informationZika virus: clinical and epidemiological features
Zika virus: clinical and epidemiological features Dominic Dwyer Medical Virologist, Westmead Hospital Director, ICPMR and Pathology West NSW Health Pathology dominic.dwyer@sydney.edu.au, Zika virus Flavivirus
More informationThis memo is intended to provide information to NC clinicians and laboratories regarding diagnosis, management and reporting of Zika virus infection.
May 18, 2016 (replaces version dated March 31, 2016) To: From: North Carolina Health Care Providers and Laboratories Megan Davies, MD, State Epidemiologist Scott Zimmerman, DrPH, MPH, HCLD (ABB), State
More informationZika virus infection Interim clinical guidance for Primary Care
Zika virus infection Interim clinical guidance for Primary Care Zika virus infection is a notifiable disease in Ireland under the Infectious Diseases (Amendment) Regulations 2016 (S.I.. 276 of 2016). All
More informationZIKA VIRUS OUTBREAK. JANET B. EDDY M.D. KU-WICHITA PGY2 OBSTETRICS AND GYNECOLOGY RESIDENCY Dominican Republic 2016
ZIKA VIRUS OUTBREAK JANET B. EDDY M.D. KU-WICHITA PGY2 OBSTETRICS AND GYNECOLOGY RESIDENCY Dominican Republic 2016 Zika time line 1947: 1 st isolated in rhesus monkey in Zika forest of Uganda 1 12/2013:
More informationWhat is Zika virus? What are the symptoms and complications of Zika virus infection? Are cases expected in Canada?
What is Zika virus? Zika Virus Update for Healthcare Professionals Updated June 22, 2016; italicized text indicates clarification of wording contained in previous versions. Zika virus is a Flavivirus transmitted
More informationEverything you ever wanted to know about Zika Virus Disease
Everything you ever wanted to know about Zika Virus Disease (in 14 slides) Jon Temte, MD/PhD University of Wisconsin School of Medicine and Public Health 28 January 2016 Zika Virus mosquito-borne flavivirus
More informationZIKA VIRUS. Epic and aspects of management
ZIKA VIRUS Epic and aspects of management Classification - Belong to the family Flaviviridae which are mosquitoes borne viruses such as Dengue virus ( DEN V ), West Nile virus ( WN V ), Yellow fever Virus
More informationZIKA VIRUS TESTING GUIDANCE, UPDATED 7/20/2016
Section 1: Which patients should be offered testing? SUMMARY OF CATEGORIES OF PATIENTS WHO SHOULD BE TESTED FOR ZIKA 1) Pregnant women who traveled to a Zika-affected area (see link to current list in
More informationUpdates in Infectious Diseases. Kelley Struble, DO, MS St. John Physicians Infectious Disease September 30, 2016
Updates in Infectious Diseases Kelley Struble, DO, MS St. John Physicians Infectious Disease September 30, 2016 Disclosures No financial relationships or affiliations to disclose Overview Activity Pre-Test
More informationZika Virus. Disclosure. Zika Virus 8/26/2016
Zika Virus Robert Wittler, MD Disclosure I have no relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services discussed in this CME
More informationZika Virus. Robert Wittler, MD
Zika Virus Robert Wittler, MD Disclosure I have no relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services discussed in this CME
More informationObjectives. Dengue, Chikungunya and Zika Virus Infection: Answers to Common Questions. Case 1. Dengue Introduction 10/15/2018
Dengue, Chikungunya and Zika Virus Infection: Answers to Common Questions Wayne Ghesquiere MD FRCPC Infectious Diseases Consultant Clinical Assistant Prof, UBC Victoria, BC Objectives Discuss common Arbovirus
More information: AccuPower ZIKV(DENV, CHIKV) Multiplex Real-Time RT-PCR Kit. Copyright, Bioneer Corporation. All rights reserved.
: AccuPower ZIKV(DENV, CHIKV) Multiplex Real-Time RT-PCR Kit Copyright, Bioneer Corporation. All rights reserved. 1. Offers superior diagnostic accuracy compared to immunoassay Allows precision diagnosis,
More informationEuropean Centre for Disease Prevention and Control. Zika virus disease
European Centre for Disease Prevention and Control Zika virus disease Stockholm, 19 February 2016 Background information Zika virus is a member of the Flaviviridae family and transmitted by mosquitoes
More informationZika Virus Dr Conor Doherty
Zika Virus Dr Conor Doherty Zika Virus Single stranded RNA enveloped icosahedral virus Flavivirus (e.g. dengue, yellow feve er) First described in Zika forest in Uganda in 1947 Initial enzootic monkey
More information2017 UnitedHealthcare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1146-7 Program Prior Authorization/Notification Medication Harvoni (ledipasvir/sofosbuvir) P&T Approval Date 10/2014, 2/2015,
More informationA RELOOK AT ZIKA VIRAL INFECTION AND ITS LATEST OUTBREAK IN INDIA
24 th December 2018 A RELOOK AT ZIKA VIRAL INFECTION AND ITS LATEST OUTBREAK IN INDIA BACKGROUND Zika virus infection, which erupted on a large scale in 2015-2016, has infected more than 1.5 million people.
More informationZika Virus Guidance for Medical Providers. Denise Smith, PHN, MPA Director of Disease Control Kern County Public Health Services Department
Zika Virus Guidance for Medical Providers Denise Smith, PHN, MPA Director of Disease Control Kern County Public Health Services Department Kern Perinatal Symposium March 3, 2017 CME DISCLOSURE The Planners,
More informationZika Virus. Maternal & Fetal Effects. John P. Elliott, MD Medical Director, Valley Perinatal Services Phoenix, Arizona
Zika Virus Maternal & Fetal Effects John P. Elliott, MD Medical Director, Valley Perinatal Services Phoenix, Arizona Objective of Presentation Sneeka Peeka at Zika Disclosure I have nothing to disclose
More informationZika Virus Update. Partner Webinar 05/12/2016
Zika Virus Update Partner Webinar 05/12/2016 Today s presenters Patricia Quinlisk, MD, MPH, Medical Director /State Epidemiologist Ann Garvey, DVM, MPH, MA, State Public Health Veterinarian/ Deputy State
More informationZika Virus and Control Efforts in Arizona
Zika Virus and Control Efforts in Arizona Irene Ruberto, MPH, PhD Epidemiologist Office of Infectious Disease Services Arizona Department of Health Services November 10, 2016 Goal by Humbletree (cc by-nc
More informationZika Virus Basics. Flaviviridae Flavivirus Disease Vector Vaccine *Dengue (serotypes 1-4) Zika Virus Basics. Zika Virus Transmission Cycle
Zika: Infection,, and Protection Roxanne P. Liles, Ph.D., MLS(ASCP) CM Assistant Professor of Biology Louisiana State University at Alexandria 318-473-6518 rliles@lsua.edu Zika Virus Basics Virion: Enveloped
More informationParent drug: hours. Not reported Parent drug: 0.4 hours Major metabolite (GS ): 27 hours. ~61% to 65% bound to human plasma proteins
Brand Name: Sovaldi Generic Name: sofosbuvir Manufacturer 3 : Gilead Sciences Inc. Drug Class 1,2 : Antiinfective, Antihepaciviral, Anti-HCV, NS5B polymerase inhibitor Uses: Labeled 1,2,3,4,5 : Chronic
More informationZIKA PRESENTED BY DENNIS QUERTERMOUS, DIANNA HUNTER, MERCEDES RUTLEDGE, AND DRE'ANDRIA THOMPSON
ZIKA PRESENTED BY DENNIS QUERTERMOUS, DIANNA HUNTER, MERCEDES RUTLEDGE, AND DRE'ANDRIA THOMPSON ZIKA OVERVIEW Family: Flaviviridae Genus: Flavivirus Enveloped, single-stranded RNA virus First identified
More informationRelevant Communicable Diseases in HCT/Ps
Relevant Communicable Diseases in HCT/Ps Phyllis I. Warkentin, MD Professor of Pathology and Pediatrics University of Nebraska Medical Center FACT Chief Medical Officer Relevant Communicable Diseases in
More informationSovaldi Ribavirin. Sovaldi (sofosbuvir) with Ribavirin (Copegus, Moderiba, Rebetol, RibaPak, Ribasphere, RibaTab, ribavirin) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Sovaldi Ribavirin Page: 1 of 7 Last Review Date: December 3, 2015 Sovaldi Ribavirin Description
More informationThe chemical name of acyclovir, USP is 2-amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-6Hpurin-6-one; it has the following structural formula:
Acyclovir Ointment, USP 5% DESCRIPTION Acyclovir, USP, is a synthetic nucleoside analogue active against herpes viruses. Acyclovir ointment, USP 5% is a formulation for topical administration. Each gram
More informationMosquito Control Update. Board of County Commissioners Work Session February 16, 2016
Mosquito Control Update Board of County Commissioners Work Session February 16, 2016 1 Presentation Overview Mosquito Control Division Mosquito-borne Diseases Control Techniques Outlook 2 Mosquito Control
More informationSofosbuvir (Sovaldi) Drug Summary. Class and Mechanism. Table of Contents
Hepatitis C Online PDF created July 12, 2018, 1:44 pm Sofosbuvir (Sovaldi) Table of Contents Sofosbuvir Sovaldi Editor's Summary Drug Summary Class and Mechanism Manufacturer for United States Cost and
More informationZika Virus in the Primary Care Setting
Zika Virus in the Primary Care Setting Monica McArthur, MD PhD Assistant Professor of Pediatrics Center for Vaccine Development University of Maryland School of Medicine Maryland Chapter ACP Meeting 17
More informationVector-Borne Diseases Update: Maricopa County
Vector-Borne Diseases Update: Maricopa County Craig Levy, Epizoologist, Office of Epidemiology WeArePublicHealth.org twitter.com/maricopahealth facebook.com/mcdph Emerging Arboviruses Zika Virus Chikungunya
More informationZika Virus. It may be devastating, But we might just get one step ahead of it. Learning in Retirement Winter 2017 Daniel Burnside. photo: Newsweek.
Zika Virus It may be devastating, But we might just get one step ahead of it Learning in Retirement Winter 2017 Daniel Burnside photo: Newsweek.com INTRODUCTION TO VIRUSES STRUCTURE GENOME LIFE CYCLE
More informationNew York State HCV Provider Webinar Series. Side Effects of Therapy
New York State HCV Provider Webinar Series Side Effects of Therapy Objectives Understand the basics of HCV therapy Review the currently available regimens for treatment of HCV Appreciate side effects related
More information2017 UnitedHealthcare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2052-10 Program Prior Authorization/Medical Necessity Medication Harvoni (ledipasvir/sofosbuvir) P&T Approval Date 4/2015, 8/2015,
More informationClinical Policy: Diagnostic Testing for Zika Virus Reference Number: CP.MP.111 Effective Date: 06/16
Clinical Policy: Diagnostic Testing for Zika Virus Reference Number: CP.MP.111 Effective Date: 06/16 Last Review Date: 05/16 Revision Log See Important Reminder at the end of this policy for important
More informationWelcome All. Western Australia Oncology Menopause Endometriosis New Mothers
Welcome All Western Australia ZIKA VIRUS What s the latest? Dr Clay Golledge COUNTRIES WITH ONGOING ZIKA CIRCULATION American Samoa Curacao Guyana Nicaragua Tonga Barbados Dominican Republic Haiti Panama
More informationCarol M. Smith, M.D., M.P.H. Commissioner of Health and Mental Health Ulster County Department of Health and Mental Health May 20, 2016
Carol M. Smith, M.D., M.P.H. Commissioner of Health and Mental Health Ulster County Department of Health and Mental Health May 20, 2016 Michael Hein County Executive Zika virus was first discovered in
More informationHepatitis C in Australia:
Hepatitis C in Australia: Epidemiology and Clinical Presentation (and a bit of virology ) A/Prof Mark Douglas Hepatitis C - Distribution Te and Jensen 2010 Clin Liver Dis Hepatitis C Epidemiology Estimated
More informationZIKA AND MOSQUITO- BORNE ILLNESSES
ZIKA AND MOSQUITO- BORNE ILLNESSES Steven M. Presley, Ph.D. Professor, Environmental Toxicology São Paulo Research Foundation (FAPESP) Week 21 & 22 September 2017 BIOLOGICAL THREAT RESEARCH LABORATORY
More informationZika. Nicole Evert, MS Zoonosis Control Branch Department of State Health Services Austin, Texas
Zika Nicole Evert, MS Zoonosis Control Branch Department of State Health Services Austin, Texas Family Flaviviridae, genus Flavivirus Vectors: Aedes aegypti and Aedes albopictus Maintained in a human-mosquito-human
More informationZika Virus Outbreak in the Americas. J. David Beckham MD Associate Professor of Medicine Division of Infectious diseases University of Colorado SOM
Zika Virus Outbreak in the Americas J. David Beckham MD Associate Professor of Medicine Division of Infectious diseases University of Colorado SOM Learning Objectives Understand the pathogenesis of West
More informationZika Virus. Lee Green Vector-Borne Epidemiologist Indiana State Department of Health. April 13, 2016
Zika Virus Lee Green Vector-Borne Epidemiologist Indiana State Department of Health April 13, 2016 What Is It? Flavivirus WNV Dengue St. Louis Encephalitis Yellow Fever Tick Borne Encephalitis Single stranded
More informationZika Virus A Public Health Emergency of Olympic Proportions
Zika Virus A Public Health Emergency of Olympic Proportions Carrie L. Byington M.D.** HA and Edna Benning Presidential Professor Division of Pediatric Infectious Diseases ** With Thanks to Andrew Pavia,
More informationMercer MRC A Newsletter for and about our volunteers
Mercer MRC A Newsletter for and about our volunteers May 2017 Volume 1, Issue 5 Brian Hughes, County Executive Marygrace Billek, Director, Dept. of Human Services Lyme Disease Awareness Month May is Lyme
More informationKeeping Microbes at our Doorstep
Keeping Microbes at our Doorstep Mark Loeb MD McMaster University AMMI CANADA-CACMID Plenary on Global Health, Vancouver March 31, 2016 Infection Control Objectives The challenge of anticipating risk Proving
More informationSovaldi (sofosbuvir) with PegIntron (peginterferon alfa-2b) and Ribavirin (Copegus, Moderiba, Rebetol, RibaPak, Ribasphere, RibaTab, ribavirin)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.24 Subject: Sovaldi PegIntron Ribavirin Page: 1 of 6 Last Review Date: November 30, 2018 Sovaldi PegIntron
More informationZIKA: is South Africa at risk? Lucille Blumberg National Institute for Communicable Diseases South Africa
ZIKA: is South Africa at risk? Lucille Blumberg National Institute for Communicable Diseases South Africa 18 th April 1947; Rhesus macaque (no 766) with fever Filtrable transmissable agent The absence
More informationThe Zika Crisis: Where, What and USG/WHO? Brian R. Moyer BRMoyer & Associates, LLC Bedford, NH
2016 National Biotechnology Conference, Boston, May 18th The Zika Crisis: Where, What and USG/WHO? Brian R. Moyer BRMoyer & Associates, LLC Bedford, NH 03110 bmoyernh@gmail.com 2016 National Biotechnology
More informationCLINICAL CHARACTERISTICS AND METEOROLOGICAL PATTERNS OF ZIKA VIRUS INFECTION IN CHIANG MAI PROVINCE, THAILAND
Zika virus infection in Chiang Mai, Thailand CLINICAL CHARACTERISTICS AND METEOROLOGICAL PATTERNS OF ZIKA VIRUS INFECTION IN CHIANG MAI PROVINCE, THAILAND Wasan Katip and Purida Wientong Department of
More information2017 SCAAP Summer Conference. Lilian Peake, MD, MPH
2017 SCAAP Summer Conference Lilian Peake, MD, MPH 1. Mosquito-borne Diseases 2. Challenges to Preventing and Controlling Mosquito-borne Diseases 3. Effects of Zika Virus on Child Health None Accelerating
More informationAs suggested by one fellow student, please consider the CDC's "Final Rules for Control of Communicable Diseases: Interstate and Foreign
As suggested by one fellow student, please consider the CDC's "Final Rules for Control of Communicable Diseases: Interstate and Foreign http://www.cdc.gov/quarantine/ aboutlawsregulationsquarantineisolatio
More informationGeneral Description. Significance
General Description The Zika virus is a member of the Flavivirus family, and is a small, enveloped virus (easy to kill with a hospital disinfectant). Zika virus is an emerging mosquito-borne virus that
More informationZika Virus. Beata Casanas, DO FACP FIDSA. Associate Professor of Infectious Diseases University of South Florida
Zika Virus Beata Casanas, DO FACP FIDSA Associate Professor of Infectious Diseases University of South Florida Zika Virus Definition: Arthropod-borne flavivirus transmitted by mosquitoes The virus is related
More informationZika Virus. Division of Infectious Disease Department of Internal Medicine Global Health Program Conference Dora Lebron, MD Alexandra Stang, MD
Zika Virus Division of Infectious Disease Department of Internal Medicine Global Health Program Conference Dora Lebron, MD Alexandra Stang, MD Zika Virus ZIKV is a mosquito-borne ssrna flavivirus from
More informationFIRST CONFIRMED CASE OF IMPORTED ZIKA VIRUS IN HOUSTON, TEXAS. Preventing Transmission
FIRST CONFIRMED CASE OF IMPORTED ZIKA VIRUS IN HOUSTON, TEXAS Preventing Transmission Objectives Discuss the epidemiology of Zika virus Describe the Zika case investigation of the first confirmed case
More informationPresentation Overview
Presentation Overview Characteristics of Zika virus Characteristics of Zika virus infection Epidemiology and outbreaks Vector and transmission Clinical symptoms Diagnosis and testing Treatment and prevention
More informationZika Update. Florida Department of Health Broward. Paula Thaqi, MD, MPH Director
Zika Update Florida Department of Health Broward 1 Paula Thaqi, MD, MPH Director Zika Virus Over 750,000 reported cases in the Americas Over 36,000 cases in U.S. territories Over 5,000 imported case sin
More informationUPDATE ON ZIKA VIRUS INFECTION
IMPORTANCE UPDATE ON ZIKA VIRUS INFECTION Robert A. Broughton, M.D. Professor of Pediatrics Division of Infectious Diseases E-mail: rbrough@uky.edu WHO declared Zika a Public Health Emergency of International
More informationZika Virus Identifying an Emerging Threat. Florida Department of Health in Miami-Dade County Epidemiology, Disease Control, & Immunization Services
Zika Virus Identifying an Emerging Threat Florida Department of Health in Miami-Dade County Epidemiology, Disease Control, & Immunization Services What is Zika Virus? Zika virus is a vector-borne disease
More informationZika Virus What Every Woman Needs to Know
Zika Virus What Every Woman Needs to Know Carrie L. Byington, MD The Jean and Thomas McMullin Professor and Dean of Medicine Senior Vice President Health Science Center Vice Chancellor for Health Services
More informationNorth Carolina Department of Health and Human Services Division of Public Health
North Carolina Department of Health and Human Services Division of Public Health Pat McCrory Governor February 8, 2016 (replaces version dated January 28, 2016) Richard O. Brajer Secretary Daniel Staley
More informationZIKA UPDATE NOVEMBER Ministry of Health, Barbados
ZIKA UPDATE NOVEMBER 2016 Ministry of Health, Barbados Zika Virus Disease Objectives By the end of this presentation you should be able: To recount the track of the current global Zika virus epidemic To
More informationDaklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Daklinza Sovaldi Page: 1 of 7 Last Review Date: June 24, 2016 Daklinza Sovaldi Description Daklinza
More informationHepatitis C Resistance Associated Variants (RAVs)
Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure
More informationFrom Mosquitos to Humans: Genetic evolution of Zika Virus
Article: From Mosquitos to Humans: Genetic evolution of Zika Virus Renata Pellegrino, PhD Director, Sequencing lab Center for Applied Genomics The Children s Hospital of Philadelphia Journal Club Clinical
More informationSovaldi (sofosbuvir) with Pegasys (peginterferon alfa-2a) and Ribavirin (Copegus, Moderiba, Rebetol, RibaPak, Ribasphere, RibaTab, ribavirin)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.25 Subject: Sovaldi Pegasys Ribavirin Page: 1 of 6 Last Review Date: December 8, 2017 Sovaldi Pegasys
More informationThe problem with TORCH screening
: Beyond TORCHeS TORCH or STORCH-a helpful mnemonic? Toxoplasma Other Rubella CMV HSV (HIV) Syphilis 3 The problem with TORCH screening TORCH-first proposed by Nahmias et.al. (Pediatr Res 1971) Toxo, Rubella,
More informationZika Virus (ZIKV) Rosanna W Peeling London School of Hygiene & Tropical Medicine Director, International Diagnostics Centre.
Zika Virus (ZIKV) Rosanna W Peeling London School of Hygiene & Tropical Medicine Director, International Diagnostics Centre www.idx-dx.org ZiKa Virus (ZIKV) Zika virus (ZIKV) is an RNA virus of the Flaviviridae
More informationNOTES. The Naturally Attenuated Kunjin Strain of West Nile Virus Shows Enhanced Sensitivity to the Host Type I Interferon Response
JOURNAL OF VIROLOGY, June 2011, p. 5664 5668 Vol. 85, No. 11 0022-538X/11/$12.00 doi:10.1128/jvi.00232-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. NOTES The Naturally Attenuated
More informationNS1 Protein Expression in the JaOArS982 Strain of Japanese Encephalitis Virus Does Not Enhance Virulence in Mice
Tropical Medicine and Health Vol. 43 No.4, 2015, 233 237 doi: 10.2149/tmh.2015-27 Copyright 2015 by The Japanese Society of Tropical Medicine 233 Short Communications NS1 Protein Expression in the JaOArS982
More informationMosquito Threats in Burbank West Nile virus and Zika Update. Presented by Kelly Middleton, Director of Community Affairs
Mosquito Threats in Burbank West Nile virus and Zika Update Presented by Kelly Middleton, Director of Community Affairs The District at a Glance An independent special district formed under authority of
More informationPrevention of transfusion-transmitted arboviruses in French Polynesia
Prevention of transfusion-transmitted arboviruses in French Polynesia D Musso 1, V Richard 1, J Green 2,J Broult 3, M Aubry 1 1. Institut Louis Malardé, Tahiti, French Polynesia 2. Cerus Corporation, California,
More informationFY 2017 President s Budget Request Overview for the National Center on Birth Defects and Developmental Disabilities
National Center on Birth Defects and Developmental Disabilities FY 2017 President s Budget Request Overview for the National Center on Birth Defects and Developmental Disabilities Sascha Chaney Associate
More informationWhat is Zika virus (Zika)?
Zika Virus Basics What is Zika virus (Zika)? Viral infection caused by the bite of an infected mosquito Linked to serious birth defects and other poor pregnancy outcomes in babies of mothers who were infected
More informationManagement of HBV in KidneyTransplanted Patients Dr.E.Nemati
Management of HBV in KidneyTransplanted Patients Dr.E.Nemati Hepatitis B virus (HBV) infection Hepatitis B virus (HBV) infection confers a significantly negative impact on the clinical outcomes of kidney
More informationGeographic distribution ZIKV
Shelley M. Wood, RN, BSN, CEN March 16, 2016 Geographic distribution ZIKV 1947 2007 http://www.ncbi.nlm.nih.gov/pmc/articles/pmc2819875/ 1 Current Active Zika transmission WHO declared global health threat
More informationSexual & Reproductive Health in the Context of Zika Virus
Contents 1 The Zika Epidemic & its Impact on Health 2 Transmission, Pregnancy & Human Rights 3 GTR s Program & Public Policy Recommendations 4 GTR's Recommendations for Health Care Providers 5 GTR's Sexual
More informationZIKA VIRUS. Annanya Gangopadhyay*, Shubhrajit Mantry, Abhinay Chhetri, Sudip das
ZIKA VIRUS Annanya Gangopadhyay*, Shubhrajit Mantry, Abhinay Chhetri, Sudip das, Himalayan Pharmacy Institute, Majhitar, Rangpo, E. Sikkim 737136, INDIA ARTICLE INFO: Article history: Received: 02 December
More informationDiscovery of Potent, Highly Selective, Broad Spectrum Antivirals
Discovery of Potent, Highly Selective, Broad Spectrum Antivirals Fred Hutch/Merck Infectious Disease Summit May 10, 2018 Sam Lee, Ph.D. 1 Forward Looking Statements This presentation contains forward-looking
More informationWest Nile Virus. By Frank Riusech
West Nile Virus By Frank Riusech Disease Etiology: West Nile virus(wnv), genus, flavivirus is positive- stranded RNA arbovirus (arthropod- borne), belonging to the Flaviviridae family. Included in this
More information